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Aim of the study: This study was made to investigate the antidiabetic, antioxidant and hypolipidemic potential of
Cinnamomum tamala, (Buch.-Ham.) Nees & Eberm (Tejpat) oil (CTO) in streptozotocin (STZ) induced diabetes in rats
along with evaluation of chemical constituents.
Materials and methods: The GC-MS (Gas chromatography–mass spectrometry) analysis of the oil showed
31 constituents of which cinnamaldehyde was found the major component (44.898%). CTO and cinnamaldehyde
was orally administered to diabetic rats to study its effect in both acute and chronic antihyperglycemic models. The
body weight, oral glucose tolerance test and biochemical parameters viz. glucose level, insulin level, liver glycogen
content, glycosylated hemoglobin, total plasma cholesterol, triglyceride and antioxidant parameters were estimated
for all treated groups and compared against diabetic control group.
Results: CTO (100 mg/kg and 200 mg/kg), cinnamaldehyde (20 mg/kg) and glibenclamide (0.6 mg/kg) in
respective groups of diabetic animals administered for 28 days reduced the blood glucose level in streptozotocin
induced diabetic rats. There was significant increase in body weight, liver glycogen content, plasma insulin level
and decrease in the blood glucose, glycosylated hemoglobin and total plasma cholesterol in test groups as
compared to control group. The results of CTO and cinnamaldehyde were found comparable with standard drug
glibenclamide. In vitro antioxidant studies on CTO using various models showed significant antioxidant activity.
In vivo antioxidant studies on STZ induced diabetic rats revealed decreased malondialdehyde (MDA) and increased
reduced glutathione (GSH).
Conclusion: Thus the investigation results that CTO has significant antidiabetic, antioxidant and
hypolipidemic activity.
Keywords: Cinnamomum tamala, Cinnamaldehyde, Glibenclamide, Hyperglycaemia, StreptozotocinIntroduction
Diabetes mellitus is one of the major global health and
economic problem, characterized by high levels of blood
glucose resulting from defects in insulin production, in-
sulin action, or both. Diabetes has affected 6% of the
world’s population [1,2]. Type II diabetes accounts for* Correspondence: sharmask71@rediffmail.com
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reproduction in any medium, provided the or90–95% of all diabetic cases [2]. Long-term complica-
tions viz; cardiomyopathy, angiopathy, nephropathy etc.
are a major cause of morbidity in patients with diabetes
mellitus. Hyperlipidemia and oxidative stress frequently
co-exist with diabetes mellitus [3]. The increased blood
glucose levels in diabetes produce superoxide anions,
which generate hydroxyl radicals via Haber Weiss reac-
tion, resulting in peroxidation of membrane lipids and
protein glycation causing oxidative damage of cell mem-
branes. These radicals further damage other important
biomolecules including carbohydrates, proteins andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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important role to protect the human body against dam-
age caused by reactive oxygen species. Hence com-
pounds with both hypoglycemic and antioxidant
properties would be useful antidiabetic agent.
Some studies have suggested that essential oils may be
useful in the treatment of insulin resistance and type II
diabetes mellitus, and various oils have been used as
therapeutic agents for years without any significant ad-
verse health effects. Cinnamomum tamala (Buch.-Ham.)
Nees & Eberm (Tejpat) (Lauraceae), a volatile oil con-
taining tree is commercially known as Indian cassia. It is
used in traditional medicines as an astringent, stimulant,
diuretic, carminative and in cardiac disorders [5]. The
leaves of Cinnamomum tamala have been reported to
possess antidiabetic, antioxidant [6], antidiarrhoeal [7],
antihyperlipidemic [8], antioxygenic [9], anti-inflammatory
[10], acaricidal [11], hepatoprotective [12], gastroprotec-
tive [13], antibacterial and immunomodulatory activities
[14]. The essential oil from Cinnamomum species can
be extracted easily by hydro distillation [15]. The oil has
been widely used as a flavoring agent and additives for
centuries in the food industries. As far as we know, the
effect of oil on the blood profiles in diabetic models has
not been studied. In light of these findings, we carried
out this study for the evaluation of antidiabetic, hypoli-
pidemic and antioxidant potential of the CTO.
Materials and methods
Drugs and chemicals
The drugs and chemicals used in the study were gliben-
clamide (Torrent Pharmaceutical, Ahmadabad), strepto-
zotocin, heparin (SRL, India), EDTA (Hi-media Lab. Pvt
Ltd., Mumbai, India), Ellman’s reagent (5,5’-dithiobis-(2-
nitro-benzoic acid); DTNB), sodium sulphate, methanol,
pyridine, anthrone, thiourea, benzoic acid, sodium chlor-
ide (SD Fine Chem Ltd., Mumbai, India). All the chemi-
cals used in the study were of analytical grade.
Preparation of oil
The dried leaves of Cinnamomum tamala procured from
local market of Hisar which were identified and authenti-
cated by Dr. H. B. Singh, Head, Raw Materials Herbarium
and Museum, National Institute of Science Communica-
tion and Information Resources (Ref. NISCAIR/RHMD/
Consult/-2011-12/1858/158), Delhi (India). The leaves
were cut in to small pieces and oil was extracted with the
help of Clevenger apparatus. The percentage yield of the
oil was found to be 0.45%.
Gas chromatography–mass spectrometry (GC-MS) analysis
The GC-MS analysis of the essential oil was performed
using Agilent 7890A GC system equipped with MS de-
tector 5975C inert XL EI/CI MSD having automaticsampler CTC analysis CombiPAL robotic arm. For GC/
MS detection, an electron ionization system with
ionization energy of 70 eV was used. Helium gas was
used as the carrier gas at a constant flow rate of 1 ml/
min. The inlet temperature was set at 270°C. The speci-
fication of the capillary column used was Agilent
19091S-433: 1548, 52849 HP-5MS 5% Phenyl Methyl
Silox 30 m× 250 μm x 0.25 μm HP-5MS. The oven
temperature was programmed from 80°C to 300°C. The
diluted samples (1/100, v/v, in Hexane) of 2 μL were
injected.
Identification of constituents
The relative percentage amount of each component was
calculated by comparing its average peak area to the
total areas. The oils components were identified by
matching their recorded mass spectra with the data bank
mass spectra (Search library Database/W9N08.L) and by
comparing their retention indices relative to a series of
n-hydrocarbons (C7–C23) with literature values [16].
Experimental animals
Healthy male albino wistar rats (150–250 g, 60–90 days
old) were procured from Disease Free Small Animal
House, Chaudhary Charan Singh Haryana Agriculture
University, Hisar (Haryana). The rats were housed in
(Polycarbonate cage size: 29 × 22 × 14 cm) under labora-
tory standard conditions (25 ± 3°C:35–60% humidity)
with alternating light and dark cycle of 12 h each and
were feed fed with a standard rat pellet diet (Hindustan
Lever Ltd, Mumbai, India) and water ad libitum. The
experimental protocol was approved by Institutional
Animals Ethics Committee (IAEC) and animal care was
taken as per the guidelines of Committee for the Pur-
pose of Control and Supervision of Experiments on Ani-
mals (CPCSEA), Govt. of India (Registration No. 0436).
Acute toxicity studies
Healthy adult albino wistar rats of both sex, starved
overnight were divided in to eight groups (n = 6) and
were orally fed with the oil of Cinnamomum tamala in
the increasing dose of 10, 50, 100, 200, 500, 1000, 1500
and 2000 mg/kg body weight. The rats were observed
continuously for 2 h for behavioral changes and after 24
and 72 h for any lethality [17].
Induction of diabetes
Type II diabetes mellitus (NIDDM) was induced in over-
night fasted animals by a single intraperitoneal injection
of 50 mg/kg STZ in 0.1 M citrate buffer (pH-4.5) in a
volume of 1 ml/kg body weight. Diabetes was developed
and stabilized over a period of 7 days. Diabetes was con-
firmed by the elevated blood glucose levels determined
at 72 h and on 7th day after injection. Only rats
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antidiabetic study. Blood was collected by intraocular
route [18].
Experimental design
After the induction and confirmation of diabetes, Rats
were divided into the following groups comprising six
rats in each group.
For acute antihyperglycemic model
In the acute antihyperglycemic models the study was
carried out for 4 hours to check whether the plant have
some effect or not.
Group 1 Normal rats were administered 2% Dimethyl
sulfoxide (DMSO).
Group 2 Diabetic control rats were administered 2%
Dimethyl sulfoxide (DMSO).
Group 3 Diabetic animals were administered
glibenclamide (0.6 mg/kg p.o).
Group 4 Diabetic animal were administered orally
100 mg/kg of CTO.
Group 5 Diabetic animal were administered orally
200 mg/kg of CTO.
Group 6 Diabetic animal were administered orally
20 mg/kg of Cinnamaldehyde.
For chronic antihyperglycemic model
In the chronic antihyperglycemic models the study was
carried out for 28 days to study the various parameters
of the diabetes and hyperlipidemia to confirm the
antidiabetic, antioxidant and hypolipidemic activity of
Cinnamomum tamala oil and its main constituent
cinnamaldehyde in streptozotocin induced diabetes in
rats.
Group 7 Normal rats were administered 2% Dimethyl
sulfoxide (DMSO).
Group 8 Diabetic control rats were administered 2%
Dimethyl sulfoxide (DMSO).
Group 9 Diabetic animals were administered
glibenclamide (0.6 mg/kg p.o).
Group 10 Diabetic animal were administered orally
100 mg/kg of CTO.
Group 11 Diabetic animal were administered orally
200 mg/kg of CTO.
Group 12 Diabetic animal were administered orally
20 mg/kg of Cinnamaldehyde.
Sample collection
Blood sample
The 24 h fasted animals were sacrificed by cervical de-
capitation on 29th day of treatment. Trunk blood was
collected in heparinized tubes and the plasma wasobtained by centrifugation at 5000 rpm for 5 min. for
the determination of biochemical parameters; glucose,
insulin, cholesterol, glycosylated hemoglobin, malondial-
dehyde (MDA), reduced glutathione (GSH) etc.
Collection of organs
The rats were anaesthetized by using the overdose of
anesthesia, and tissue sample were taken for assessment
of biochemical parameters.
Estimation of plasma glucose and cholesterol
Plasma cholesterol and glucose level were measured by
commercial supplied biological kit Erba Glucose Kit
(GOD-POD Method) and Erba Cholesterol Kit (CHOD-
PAP Method) respectively using Chem 5 Plus-V2 Auto-
analyser (Erba Mannhein Germany) in plasma sample
prepared as above. Glucose and cholesterol values were
calculated as mg/dl blood sample.
Estimation of glycosylated hemoglobin (Hb1Ac)
Glycosylated hemoglobin was measured using commer-
cial supplied biological kit (Erba Diagnostic) in plasma
sample prepared as above using Chem 5 Plus-V2 Auto-
analyser (Erba Mannhein Germany). Values are
expressed as the percent of total hemoglobin.
Estimation of liver glycogen content
Liver glycogen estimation was done by the method as
described by Seifter et al. (1950) [19]. Immediately after
excision from the animal, 1 g of the liver was dropped
into a previously weighed test tube containing 3 ml of
30% potassium hydroxide solution. The weight of the
liver sample was determined. The tissue was then
digested by heating the tube for 20 min in boiling water
bath, and following this the digest was cooled, trans-
ferred quantitatively to a 50 ml volumetric flask, and
diluted to the mark with water. The contents of the flask
were then thoroughly mixed and a measured portion
was then further diluted with water in a second volumet-
ric flask so as to yield a solution of glycogen of 3–30 μg/
ml. Five ml aliquots of the final dilution were then pip-
ette into Evelyn tube and the determination with
anthrone was carried out. The amount of glycogen in
the aliquot used was then calculated using the following
equation:
μg of glycogen inaliquot ¼ 100 U=1:11S
U is the optical density of unknown solution. S is the
optical density of the 100 μg glucose and 1.11 is the fac-
tor determined by Morris in 1948 for the conversion of
the glucose to the glycogen.
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Serum insulin level was measured by an enzyme-linked
immunosorbent assay (ELISA) procedure using Merco-
dia rat insulin ELISA kit. Briefly, the solid phase two-site
enzyme immunoassay is based on the direct sandwich
technique in which two monoclonal antibodies are
directed against separate antigenic determinants 35 (epi-
topes) on the insulin molecule. During incubation,
insulin in the sample reacts with peroxidase-conjugated
anti-insulin antibodies and anti-insulin antibodies bound
to the micro titration well. After washing three times,
unbound enzyme labeled antibody was removed. The
bound conjugated insulin was detected by reacting
with 3, 3’, 5, 5’-tetramethylbenzidine. The reaction
was stopped by adding acid to give a colorimetric end-
point and optical density was measured with a micro
plate auto reader (Bio-tek Instrument Inc., USA) at a
wavelength of 450 nm. The serum insulin is expressed
as μg/l.
In vitro antioxidant activity
Diphenyl-picryl-hydrazyl radical scavenging (DPPH) Assay
The antioxidant activity of the oil was measured in
terms of hydrogen donating or radical scavenging ability,
using the stable radical, DPPH [20]. A methanolic stock
solution (50 ml) of the antioxidant (concentrations of
stock solutions were 1.0, 2.0, 4.0, 6.0, 8.0, 10, 12, 16,
20.0, 25, 30, 40.0, 45.0 and 50.0 g/l) was placed in a cu-
vette, and 2 ml of 6 × 10-5 M methanolic solution of
DPPH was added. Absorbance measurements com-
menced immediately. The decrease in absorbance at
517 nm was determined by Perkin-Elmer spectropho-
tometer after 1 h for all samples. Methanol was used to
zero the spectrophotometer. The absorbance of the
DPPH radical without antioxidant, i.e. the control, was
measured daily. Special care was taken to minimize the
loss of free radical activity of the DPPH radical stock so-
lution [21]. All determinations were performed in tripli-
cate. The percentage inhibition of the DPPH radical by
the samples was calculated according to the formula of
Yen and Duh (1994) [22]:
The percentage of inhibition was calculated using the
formula,
Inhibition %ð Þ ¼ absorbanceof controlð
absorbanceof test=absorbanceof controlÞ
 100
Hydrogen peroxide radical scavenging (H2O2) assay
The ability of plant extracts to scavenge hydrogen perox-
ide is determined according to the method of Ruch et al.
(1989) [23]. A solution of hydrogen peroxide (40 mM)
was prepared in phosphate buffer (50 mM, pH 7.4). Theconcentration of hydrogen peroxide was determined by
absorption at 230 nm using a spectrophotometer. The
oil (20–60 μg/ml) in distilled water was added to hydro-
gen peroxide and absorbance at 230 nm was determined
after 10 min against a blank solution containing phos-
phate buffer without hydrogen peroxide. The percentage
of hydrogen peroxide scavenging was calculated as fol-
lows:
% Scavenged H2O2ð Þ ¼ A0  A1=A0ð Þ  100
Where; A0 is the absorbance of control and A1 is the
absorbance of test. Butylated hydroxy toluene (BHT)
was used as a positive control.Metal chelating activity
Ferrozine can quantitatively chelate with Fe2+ and form
a complex with a red color. This reaction is limited in
the presence of other chelating agents and results in a
decrease of the red color of the ferrozine-Fe2+ com-
plexes. Measurement of the color reduction estimates
the chelating activity to compete with ferrozine for the
ferrous ions [24]. The chelation of ferrous ions is esti-
mated using the method of Dinis et al. (1994) [25]. The
oil (0.1 ml) was added to a solution of 0.5 ml ferrous
chloride (0.2 mM). The reaction was initiated by the
addition of 0.2 ml of ferrozine (5 mM) and incubated at
room temperature for 10 min and then the absorbance
measured at 562 nm. Ascorbic acid was used as a posi-
tive control.In vivo antioxidant activity
Estimation of MDA level
Malondialdehyde (MDA), an index of free radical gener-
ation/lipid peroxidation, was determined as described by
Okhawa et al. 1979 [26]. Briefly, the reaction mixture
consisted of 0.2 ml of 8.1% sodium lauryl sulphate,
1.5 ml of 20% acetic acid (pH 3.5) and 1.5 ml of 0.8%
aqueous solution of thiobarbituric acid added to 0.2 ml
of blood plasma. The mixture was made up to 4.0 ml
with distilled water and heated at 95°C for 60 min. After
cooling the contents under running tap water, 5.0 ml of
n-butanol and pyridine (15:1 v/v) and 1.0 ml of distilled
water was added. The contents were centrifuged at
about 3000 rpm for 10 min. The organic layer was sepa-
rated out and its absorbance was measured at 532 nm
using double beam UV-Visible spectrophotometer
(Systronics 2203, Bangalore, India) against a blank.
MDA values were calculated using the extinction coeffi-
cient of MDA-thiobarbituric acid complex 1.56 × 105 l/
mol × cm and expressed as nmol/ml.
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The tissue sample (liver 200 mg) was homogenized in
8.0 mL of 0.02 M EDTA in an ice bath. The homoge-
nates were kept in the ice bath until used. Aliquots of
5.0 mL of the homogenates were mixed in 15.0 mL test
tubes with 4.0 mL distilled water and 1.0 mL of 50%
trichloroacetic acid (TCA). The tubes were centrifuged
for 15 min at approximately 3000 rpm, 2.0 mL of super-
natant was mixed with 4.0 ml of 0.4 M Tris buffer pH
8.9, 0.1 mL Ellman’s reagent [5,5-dithiobis-(2-nitro-
benzoic acid)] (DTNB) added and the sample shaken.
The absorbance was read within 5 min of the addition
of DTNB at 412 nm against a reagent blank with no
homogenate. Results are expressed as μmol GSH/g
tissue [27].
Statistical analysis
The data for various biochemical parameters were evalu-
ated by use of one-way ANOVA, followed by Dunnett’s
t-test using the software Sigma-Stat 3. In all the tests,
the criterion for statistical significance was p <0.05.
Results
Chemical composition of essential oil
The chromatogram of CTO by GC-MS is shown in
Figure 1. The GC-MS analysis of CTO led to the identi-
fication and quantification of 31 components (Table 1)Figure 1 GC-MS chromatogram of Cinnamomum tamala oil shows 31
plant oil.which accounted for 99.99% of the total oil. The main
volatile components of CTO were found as cinnamalde-
hyde (44.898%), Trans cinnamyl acetate (25.327%),
Ascabin (15.249%), Hydro cinnamyl acetate (3.384%),
Beta-caryophyllene (2.669%) which comprised of
91.527% of the oil.Acute toxicity study
The oral administration of graded dose of CTO to the
rats in our acute toxicity study was found to be non le-
thal up to the dose of 1000 mg/kg body weight. However
2000 mg/kg body weight of CTO caused 50% motility in
the animals.Oral glucose tolerance test
The effect of CTO on plasma glucose level after glu-
cose loading of 2 g/kg body weight orally to the dia-
betic rats is expressed in the Table 2. The blood
glucose level rises to a maximum in 60 min after glu-
cose loading. The oil (100 mg/kg and 200 mg/kg body
weight) and cinnamaldehyde (20 mg/kg body weight)
treated groups showed a significant decrease in level of
glucose as compared to control group. The oil treated
group showed a marked fall in glucose level in 90 min
to 120 min interval.peaks which indicates that 31 compounds are present in the
Table 1 Chemical composition of Cinnamomum tamala
essential oil Total components of the oil 99.99%
Sr. No. Compound Retention time % of Total
1 Alpha-pinene 3.621 0.095%
2 Camphene 3.864 0.037%
3 Benzaldehyde 4.050 1.222%
4 Beta-pinene 4.312 0.034%
5 p-cymene 5.166 0.065%
6 Beta-Phellandrene 5.270 0.106%
7 Acetophenone 6.153 0.044%
8 Linalool 6.850 0.442%
9 Beta-phenylpropionaldehyde 8.608 1.856%
10 Phenetol 8.775 0.109%
11 Benzofuran 9.006 0.185%
12 Acrolein 10.285 0.286%




15 Eugenol 14.473 0.078%
16 Hydro cinnamyl acetate 14.836 3.384%
17 Alpha-copaene 14.980 0.414%
18 Pivalic acid 15.340 0.129%
19 Cinnamyl acetate 15.450 0.091%
20 Methyl eugenol 15.909 0.107%
21 Beta-caryophyllene 16.329 2.669%
22 Valecene 16.910 0.089%
23 Tans-cinnamyl acetate 17.172 25.327%
24 Alpha-humulene 17.365 0.636%
25 Bicyclogermacrene-lepdozene 18.658 0.191%
26 Naphthalene 19.455 0.067%
27 Spathulenol 21.108 0.780%
28 Caryophyllene oxide 21.230 1.135%
29 Alpha-patchoulene 21.547 0.090%
30 Humulene oxide 21.993 0.097%
31 Ascabin 25.584 15.249%
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Administration of CTO at a dose 100 mg/kg body
weight p. o. to diabetic rats showed reduction in blood
glucose level from 356 mg/dl to 292 mg/dl at 4th h.Table 2 Effect of Cinnamomum tamala oil in Oral glucose tole
Treatment Dose Mea
0 min. 30 m
Normal —— 85±4.6 147 ±
Diabetic control —— 270 ± 8.6 399 ±
CTO 100 mg/kg 255 ± 4.8 279 ±
CTO 200 mg/kg 257 ± 4.9 282 ±
Cinnamaldehyde 20 mg/kg 252 ± 4.0 287 ±
Values are presented as mean ± S.E.M.; n = 6 in each group. One way ANOVA follow
CTO: Cinnamomum tamala oil.When the dose was increased as 200 mg/kg then the
blood glucose level decreased from 347 mg/dl to
272 mg/dl which was found significant (p < 0.01) when
compared with diabetic control. The main constituent
cinnamaldehyde also showed the decrease in blood glu-
cose level significantly (p < 0.01) when compared with
the diabetic control groups (Table 3).
Effect of CTO on diabetic rats in chronic study
In chronic study administration of CTO at the dose of
100 mg/kg body weight to diabetic rats for 28 days
showed a fall in plasma glucose level from 304 mg/dl to
201 mg/dl on 29th day when compared to 0 day value.
CTO at the dose of 200 mg/kg body weight showed a
significant (p < 0.01) fall in plasma glucose level from
312 mg/dl to 118 mg/dl on 29th day (Table 4).
Effect of CTO on body weight
An increase in the body weight of normal rats was
observed whereas the weight of diabetic control rats de-
crease from day 1 to day 29. CTO at the dose of
200 mg/kg body weight when administered to diabetic
rats showed a significant (p < 0.01) decrease in body
weight as compared to the diabetic control group. Cin-
namaldehyde and glibenclamide also showed significant
decrease (p < 0.01) in body weight (Table 5).
Effect of CTO on insulin level
Table 6 shows the level of plasma insulin in the control
and experimental groups of rats. Diabetic rats showed a
significant decrease in plasma insulin compared with
normal rats. Following dose of oral administration of
CTO, cinnamaldehyde and glibenclamide, plasma insulin
levels increased when compared to control rats.
Effect of CTO on glycosylated hemoglobin (HbA1c)
The effect of CTO and cinnamaldehyde on HbA1c in
diabetic rats is shown in the Table 6. The level of glyco-
sylated hemoglobin significantly increased (p < 0.01) in
diabetic rats as compared to normal control group. The
diabetic rats when treated with CTO and cinnamalde-
hyde for 28 days showed a significant (p < 0.01)rance test (OGTT)
n blood glucose concentration (mg/dl) ± S.E.M
in. 60 min. 90 min. 120 min.
2.3 110 ± 2.9 97 ± 3.5 89 ± 3.0
6.3 419.2 ± 3.2 369 ± 3.6 341 ± 4.9
3.9 318 ± 4.0 299 ± 5.6** 280 ± 3.2**
4.1 343 ± 3.9 286 ± 2.5** 239 ± 3.8**
5.7 356 ± 2.1 275 ± 4.2** 228 ± 2.9**
ed by Dunnett’s test **p < 0.01 vs. diabetic control;
Table 3 Acute hypoglycaemic effect of Cinnamomum tamala oil on STZ induced diabetic rats
Treatment Dose Mean blood glucose concentration (mg/dl) ± S.E.M)
0 h 1/2 h 1 h 2 h 4 h
Normal – 76 ± 4.2 80 ± 3.2 77 ± 2.5 82 ± 4.1 79 ± 5.3
Control – 340.5 ± 10.2 342 ± 11.3 346 ± 7.6 341.0 ± 6.7 332.0 ± 7.2
CTO 100 mg/kg p.o 356 ± 6.7 334.1 ± 6.2 308 ± 3.6** 301 ± 3.0** 292 ± 3.3**
CTO 200 mg/kg p.o 347 ± 1.8 324 ± 0.7* 301 ± 2.3** 295 ± 1.5** 272 ± 6.5**
Cinnamaldehyde 20 mg/kg p.o 329 ± 3.2 302 ± 4.2** 299 ± 3.2** 270 ± 4.6** 262 ± 5.3**
Glibenclamide 0.6 mg/kg p.o 334 ± 3.1 320 ± 2.9** 296 ± 3.9** 279 ± 4.9** 260.0 ± 4.2**
Values are presented as mean ± S.E.M.; n = 6 in each group. One way ANOVA followed by Dunnett’s test *p < 0.05; **p < 0.01 vs. diabetic control;
CTO: Cinnamomum tamala oil.
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treated diabetic group. The fall in glycosylated
hemoglobin level was found to be dose dependent.
Effect of CTO on hepatic glycogen
The hepatic glycogen content in diabetic rats decreased
sharply as compared to control animal (Table 6). After
chronic administration of CTO and cinnamaldehyde to
diabetic rats, a significant increased (p < 0.01) liver
glycogen content as compared to diabetic control group
was observed.
Effect of CTO on lipid profile
Table 7 shows the level of lipids in normal and tested
animals. There was a significant decrease in the level of
HDL-cholesterol and a significant increase in the levels
of total cholesterol and triglycerides in diabetic rats
when compared to normal rats. The administration of
CTO and the cinnamaldehyde reverse the level of lipids
significantly (p < 0.05 and p < 0.01).
Effect of CTO on in vitro antioxidant parameters
DPPH radical-scavenging assay
It was found that the radical- scavenging activity of
CTO increased with increasing concentrations. IC50 for
DPPH radical-scavenging activity of oil was 250 ±
1.2 μg/ml. The IC50 values for cinnamaldehyde, BHTTable 4 Chronic hypoglycaemic effect of Cinnamomum tamala
Treatment Dose Me
0th Day 7t
Normal – 80 ± 4.2 79
Control – 380 ± 7.3 379
CTO 100 mg/kg p.o 304 ± 12.4 290
CTO 200 mg/kg p.o 312 ± 5.7 269
Cinnamaldehyde 20 mg/kg p.o 334 ± 3.4 287
Glibenclamide 0.6 mg/kg p.o 328 ± 3.1 265
Values are presented as mean ± S.E.M.; n = 6 in each group. One way ANOVA follow
CTO: Cinnamomum tamala oil.and BHA were found 120 ± 0.8, 19 ± 0.1 and 18.3 ±
0.1 μg/ml respectively (Table 8).
H2O2 radical scavenging assay
The CTO was capable of scavenging hydrogen peroxide
in a concentration- dependent manner. IC50 for H2O2
scavenging activity was 180 ± 1.4 μg/ml. The IC50 values
for cinnamaldehyde, BHT and BHA were 140 ± 1.1, 40 ±
0.2 and 54.0 ± 0.2 μg/ml respectively (Table 8).
Metal chelating ability
Tested oil and cinnamaldehyde exhibited good Fe2+
chelating ability with IC50 value of 350 ± 1.3 and 240 ±
0.9 μg/ml. EDTA showed very strong activity (IC50 =
220 ± 0.2 μg/ml (Table 8).
Effect of CTO on in vivo antioxidant parameters
The data depicted in Table 9 indicates the effect of oil
on malondialdehyde and reduced glutathione level.
MDA level was found to be significantly higher in dia-
betic rats compared to normal rats. The oil at dose
200 mg/kg body weight p.o significantly reduced the
level of MDA in diabetic rats. GSH level was found to
be significantly lowered in diabetic rats as compared to
normal rats. The chronic administration of CTO at
200 mg/kg body weight significantly increased the level
of glutathione in diabetic rats.oil on STZ induced diabetic rats
an blood glucose concentration (mg/dl) ± S.E.M
h Day 14th Day 21st Day 28th
± 3.2 82 ± 2.5 85.5 ± 4.1 78 ± 2.1
± 7.6 384 ± 6.7 416 ± 7.2 410 ± 5.4
± 8.6** 276 ± 7.8** 250 ± 9.9** 201 ± 10.2**
± 6.3** 176 ± 5.5** 146 ± 4.5** 118 ± 5.5**
± 4.2** 188 ± 3.2** 159 ± 4.6** 124 ± 3.2**
± 2.9** 172 ± 3.9** 142 ± 4.9** 117 ± 2.7**
ed by Dunnett’s test **p < 0.01 vs. diabetic control;
Table 5 Effect of Cinnamomum tamala oil on body weight
Sr. No. Treatment Dose Initial body weight (g) Final body weight (g) Change in weight
1. Normal – 220 ± 1.1 235 ± 1.5 +15
2. Diabetic Control – 215 ± 1.8 195 ± 2.0 −20a
4. CTO 100 mg/kg p.o 230 ± 2.2 225 ± 1.0 −5
5. CTO 200 mg/kg p.o 220 ± 1.3 210 ± 1.2 −10**
6. Cinnamaldehyde 20 mg/kg p.o 230 ± 2.0 225 ± 1.4 −05**
7. Glibenclamide 0.6 mg/kg p.o 220 ± 1.8 215 ± 1.1 −05**
Values are presented as mean ± S.E.M.; n = 6 in each group. One way ANOVA followed by Dunnett’s test a p < 0.01 vs. normal; **p < 0.01 vs. diabetic control;
CTO: Cinnamomum tamala oil.
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The aim of the study was to evaluate the antidiabetic,
antihyperlipidemic and antioxidant potential of the CTO
and its active constituent cinnamaldehyde in STZ
induced diabetes in rats. Diabetes mellitus causes a dis-
turbance in the uptake of glucose as well as glucose me-
tabolism. A dose of STZ as low as 50 mg/kg produces
an incomplete destruction of pancreatic beta cells even
though the rats become permanently diabetic [28]. After
treatment with a low dose of STZ many beta cells sur-
vive and regeneration is also possible [29]. Hypergly-
cemia generates abnormally high levels of free radicals
by autoxidation of glucose and protein glycation, and
oxidative stress has been reported to be a positive factor
of cardiovascular complications in STZ-induced diabetes
mellitus [30]. Hyperglycemia is associated with the gen-
eration of reactive oxygen species (ROS) causing oxida-
tive damage particularly to heart, kidney, eyes, nerves,
liver, small and large vessels and gastrointestinal system
[31]. The increased levels of plasma glucose in diabetic
rats were lowered by CTO and cinnamaldehyde admin-
istration. The antihyperglycemic action of cinnamalde-
hyde results from the potentiation of insulin from
existing beta cells of the islets of Langerhans [32].
To study the effect of CTO a preliminary investigation
was carried out using acute antihyperglycemic model
which revealed the significant reduction in glucose level.
Therefore further chronic antihyperglycemic model for a
period of 28 days to study the effect on various other
parameters viz. insulin level, liver glycogen content,Table 6 Effect of Cinnamomum tamala oil on glycosylated he
Treatment Dose HbA1c (% of Hb)
Normal – 6 ± 1.4
Diabetic Control – 10.8 ± 2.3a
CTO 100 mg/kg 9.0 ± 3.2
CTO 200 mg/kg 7.4 ± 1.6**
Cinnamaldehyde 20 mg/kg 7.0 ± 0.6**
Glibenclamide 0.6 mg/kg 6.8 ± 0.9**
Values are presented as mean ± S.E.M; n = 6 in each group. One way ANOVA follow
control; CTO: Cinnamomum tamala oil.glycosylated hemoglobin, total plasma cholesterol, trigly-
ceride and antioxidant parameters were estimated for all
treated groups and compared against diabetic control
group. The plasma glucose lowering activity was com-
pared with glibenclamide, a standard hypoglycemic drug.
Glibenclamide has been used for many years to treat dia-
betes, to stimulate insulin secretion from pancreatic beta
cells [33]. From the results of the present study, it
appears that still insulin producing cells are functioning
and the stimulation of insulin release could be respon-
sible for most of the metabolic effects. It may be sug-
gested that the mechanism of action of CTO is similar
to glibenclamide. The glucose lowering activity of CTO
may be related to both pancreatic (enhancement of insu-
lin secretion) and extra pancreatic (peripheral utilization
of glucose) mechanism. The hyperglycemic activity was
almost similar to cinnamaldehyde thereby the major
constituent responsible for this activity of CTO may be
cinnamaldehyde.
An increase in the level of glycosylated hemoglobin
(HbA1c) in the diabetic control group of rats is due to
the presence of large amount of blood glucose which
reacts with hemoglobin to form glycosylated hemoglobin
[34]. Oxidative stress increases due to the activation of
transcription factors, advanced glycated end products
(AGEs), and protein kinase C. If diabetes is persistent
for long time, the glycosylated hemoglobin is found to
increase [35]. The level of HbA1C was decreased after
the administration of CTO and its main constituent cin-
namaldehyde as compared to diabetic control group.moglobin (HbA1c), hepatic glycogen and insulin
Hepatic glycogen (mg/g wt of tissue) Insulin (micro U/ml)
75 ± 6.7 15 ± 2.2
28 ± 4.6a 7.8 ± 1.2a
46 ± 2.3* 9.8 ± 2.2
62 ± 4.6** 12 ± 2.1*
66 ± 2.3** 13 ± 1.6*
64 ± 3.4** 12.5 ± 1.8*
ed by Dunnett’s test ap < 0.01 vs. normal; *p < 0.05; **p < 0.01 vs. diabetic
Table 7 Effect of Cinnamomum tamala oil on Lipid profile
Treatment Dose Cholesterol (mg/dl) Triglyceride (mg/dl) HDL (mg/dl)
Normal – 84 ± 1.4 15 ± 2.6 60 ± 2.1
Diabetic Control – 222 ± 2.3a 40 ± 3.2a 36.4 ± 1.2a
CTO 100 mg/kg 160 ± 3.2** 28 ± 1.8** 45 ± 3.1
CTO 200 mg/kg 100 ± 1.6** 20 ± 2.3** 52 ± 2.4*
Cinnamaldehyde 20 mg/kg 110 ± 0.6** 18.2 ± 1.7** 55 ± 1.3**
Glibenclamide 0.6 mg/kg 130 ± 0.9** 14.8 ± 1.3** 51.2 ± 1.6*
Values are presented as mean ± S.E.M; n = 6 in each group. One way ANOVA followed by Dunnett’s test a p < 0.01 vs. normal; *p < 0.05; **p < 0.01 vs. diabetic
control; CTO: Cinnamomum tamala oil.
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in which the mean HbA1c was significantly decreased (P
< 0.005) in the cinnamon group (8.22% to 7.86%) com-
pared with placebo group (8.55% to 8.68%). Thus the
Cinnamon supplementation could be considered as an
additional dietary supplement option to regulate blood
glucose level along with conventional medications to
treat type 2 diabetes mellitus [36]. In diabetes mellitus,
the loss of body weight is caused by increase in muscle
wasting and catabolism of fat and proteins [37]. Due to
insulin deficiency protein content is decreased in muscu-
lar tissue by proteolysis [38]. A decrease in body weight
was registered in case of diabetic control group rats
while in tested groups the weight loss was reversed. Fatty
acid mobilisation from adipose tissue is sensitive to insu-
lin. Insulin’s most potent action is the suppression of
adipose tissue lipolysis [39]. A rise in plasma insulin
concentration of only 5 IU/ml inhibits lipolysis by 50%,
whereas a reduction in basal insulin levels result in a
marked acceleration of lipolysis [40]. We demonstrated
that CTO increased plasma insulin concentrations in
diabetic rats. Insulin levels higher than those of the con-
trol group may result in inhibition of lipolysis and
decreased plasma triglyceride and cholesterol levels.
Some studies suggest that the antihyperglycemic action
of traditional antidiabetic plant extracts may be due in
part to decreased glucose absorption in vivo [41]. This
mechanistic explanation may also apply to the actions
of CTO in lowering the triglyceride and cholesterol
level.Table 8 Effect of Cinnamomum tamala oil and positive contro
chelating Assay)
Sample DPPH Hyd
CTO 250 ± 1.2 180
Cinnamaldehyde 120 ± 0.8 140
BHT 19 ± 0.1 40 ±
BHA 18.3 ± 0.1 54 ±
EDTA – –
BHA: Butylated hydroxy aniline; BHT: Butylated hydroxy toluene; EDTA: Ethylene diamThe conversion of glucose to glycogen in the liver cells
is dependent on the extracellular glucose concentration
and on the availability of insulin which stimulates glyco-
gen synthesis over a wide range of glucose concentration
[35]. Diabetes reduces activity of glycogen synthase
thereby affecting the glycogen storage and synthesis in
rat liver and skeletal muscle [27]. Oral administration of
CTO 200 mg/kg body weight significantly increased
hepatic glycogen levels in diabetic rats possibly because
of the reactivation of the glycogen synthase system as a
result of increased insulin secretion. In the clinical study
the use of species of cinnamon (Cinnamomum zeylani-
cum) showed a beneficial effect on glycemic control
(both HbA1c and Fating plasma glucose) and the short
term (<4 months) effects of the use of cinnamon on gly-
caemic control looks promising [42]. The effect of Cin-
namomum zeylanicum is also reported on gastric
emptying, arterial stiffness, postprandial lipemia, gly-
cemia, and appetite responses to high-fat breakfast [43].
Further the work can be explored for mechanism of
action.
Conclusion
In conclusion, the present study showed that oral ad-
ministration of Cinnamomum tamala oil and its main
constituent has potential antidiabetic, antihyperlipidemic
and antioxidant effect in STZ induced diabetes in rats in
our model systems. The potent antioxidant activity may
be responsible for the antihyperglycemic and antihyperli-
pidemic effects. This investigation reveals the potentialls on in vitro Assays (DPPH, Superoxide and metal
IC50 (microgram/ml)
rogen peroxide (H2O2) Metal chelating activity
± 1.4 350 ± 1.3




mine tetra acetic acid; CTO: Cinnamomum tamala oil; –: Not tested.
Table 9 Effect of Cinnamomum tamala oil on MDA and
GSH
Treatment Dose MDA (nmol/dl) GSH ( μmol GSH/g )
Normal – 2.7 ± 0.2 40.2 ± 2.8
Diabetic Control – 5.2 ± 0.4 a 14 ± 1.15 a
CTO 100 mg/kg 4.0 ± 0.5 20 ± 2.3
CTO 200 mg/kg 3.2 ± 0.2** 32 ± 4.6**
Cinnamaldehyde 20 mg/kg 3.0 ± 0.1** 34 ± 1.1**
Glibenclamide 0.6 mg/kg 2.8 ± 0.1** 36 ± 2.8**
Values are presented as mean ± S.E.M; n = 6 in each group. One way ANOVA
followed by Dunnett’s test ap < 0.01 vs. normal; **p < 0.01 vs. diabetic control;
CTO: Cinnamomum tamala oil.
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antihyperlipidemic and antioxidant effects.
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